Benchmarking in patient's care;Benchmarking in der patientenversorgung: Depression bei der Parkinson-krankheit - Ergebnisse der pilotstudie

Nervenheilkunde

Volumn 26, Issue 4, 2007, Pages 277-280

  Althaus, A ^a,c   Kanis, T ^c   Spottke, A ^b   Eggert, K ^a   Liepelt, I ^d   Berg, D ^d   Schneider, F ^c   Dodel, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Benchmarking; Depression; PD; Quality measurement

Indexed keywords

MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE;

ALGORITHM; ARTICLE; DEPRESSION; GERMANY; HEALTH; HEALTH CENTER; HUMAN; NEUROLOGY; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; PATIENT CARE; PHYSICIAN; PILOT STUDY; PREVALENCE; QUALITY CONTROL; QUESTIONNAIRE;

EID: 34347336436     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626859     Document Type: Article

References (16)

1. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17(1): 60-67.
2. Asberg MM, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating-scale. Acta psychiatrica scandinavica 1978; 271: 5-25.
3. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993; 91(2-3): 75-109.
4. Härter MB, Scheinder F, Gaebel W. Niebling W, Berger M. Versorgungsleitlinien zur Diagnostik und Therapie depressiver Störungen in der hausärztlichen Praxis. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2003; 97: 16-35.
5. Hautzinger MM, Meyer T. Diagnostik Affektiver Störungen. Kompendium psychologische Diagnostik Band 3. Göttingen: Hogrefe 2002: 56-58.
6. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967: 427-442.
7. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006; 113(4): 211-220.
8. Löwe B, Zipfel S, Herzog W. Gesundheitsfragebogen für Patienten (PHQ-D). Karlsruhe: Pfizer 2001.
9. Oertel WH, Hoglinger GU, Caraceni T, Girotti F, Eichhorn T, Spottke AE, Krieg JC, Poewe W. Depression in Parkinson's disease. An update. Adv Neurol 2001; 86: 373-383.
10. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69(3): 308-312.
11. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8(3): 193-197.
12. Sitta P, Brand S, Schneider F, Gaebel W., Berger M., Farin E, Härter M. Faires Benchmarking der Behandlungsdauer depressiver Patienten in psychiatrisch-psychotherapeutischen Kliniken. Psychother Psych Med 2006; 56: 1-10.
13. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53(2): 175-179.
14. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20(9): 1161-1169.
15. Wittchen HU, Zaudig M, Fydrich T. SKID. Strukturiertes Klinisches Interview für DSM-IV. Achse I und II. Göttingen 1997.
16. www.benchmarking-qm.de